| Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder–a systematic literature review K Gajria, M Lu, V Sikirica, P Greven, Y Zhong, P Qin, J Xie Neuropsychiatric disease and treatment, 1543-1569, 2014 | 269 | 2014 |
| The short-term impacts of the Philadelphia beverage tax on beverage consumption Y Zhong, AH Auchincloss, BK Lee, GP Kanter American journal of preventive medicine 55 (1), 26-34, 2018 | 163 | 2018 |
| Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observational studies DY Heng, J Signorovitch, E Swallow, N Li, Y Zhong, P Qin, DY Zhuo, ... PloS one 9 (12), e114264, 2014 | 51 | 2014 |
| Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with first-line therapies for medicare patients 65 years and older with … MA Bittoni, A Arunachalam, H Li, R Camacho, J He, Y Zhong, ... Clinical lung cancer 19 (5), e629-e645, 2018 | 44 | 2018 |
| Sugar-sweetened and diet beverage consumption in Philadelphia one year after the beverage tax Y Zhong, AH Auchincloss, BK Lee, RM McKenna, BA Langellier International journal of environmental research and public health 17 (4), 1336, 2020 | 37 | 2020 |
| Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with second-line therapies for Medicare patients with advanced non–small … A Arunachalam, H Li, MA Bittoni, R Camacho, X Cao, Y Zhong, ... Clinical Lung Cancer 19 (5), e783-e799, 2018 | 35 | 2018 |
| Nonlinear trajectory of GFR in children before RRT Y Zhong, A Muñoz, GJ Schwartz, BA Warady, SL Furth, AG Abraham Journal of the American Society of Nephrology 25 (5), 913-917, 2014 | 27 | 2014 |
| Cost-effectiveness of pembrolizumab for patients with advanced, unresectable, or metastatic urothelial cancer ineligible for cisplatin-based therapy K Patterson, V Prabhu, R Xu, H Li, Y Meng, N Zarabi, Y Zhong, R Batteson, ... European Urology Oncology 2 (5), 565-571, 2019 | 22 | 2019 |
| Survival rates and health care costs for patients with advanced bladder cancer treated and untreated with chemotherapy K Flannery, X Cao, J He, Y Zhong, AY Shah, AM Kamat Clinical Genitourinary Cancer 16 (4), e909-e917, 2018 | 22 | 2018 |
| Real‐world medication persistence with single versus multiple tablet regimens for HIV‐1 treatment D Sweet, J Song, Y Zhong, J Signorovitch Journal of the International AIDS Society 17, 19537, 2014 | 21 | 2014 |
| The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States RL Slater, Y Lai, Y Zhong, H Li, Y Meng, BH Moreno, JL Godwin, T Frenkl, ... Journal of Medical Economics 23 (9), 967-977, 2020 | 16 | 2020 |
| Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma AG Bensimon, Y Zhong, U Swami, A Briggs, J Young, Y Feng, Y Song, ... Current medical research and opinion 36 (9), 1507-1517, 2020 | 15 | 2020 |
| The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas AR Macalalad, M McAuliffe, H Yang, A Kageleiry, Y Zhong, EQ Wu, ... Current Medical Research and Opinion 31 (3), 537-545, 2015 | 14 | 2015 |
| Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in Sweden T Srivastava, VS Prabhu, H Li, R Xu, N Zarabi, Y Zhong, JM Pellissier, ... European Urology Oncology 3 (5), 663-670, 2020 | 13 | 2020 |
| Physician experiences and preferences in the treatment of HR+/HER 2− metastatic breast cancer in the United States: a physician survey PL Lin, Y Hao, J Xie, N Li, Y Zhong, Z Zhou, JE Signorovitch, EQ Wu Cancer Medicine 5 (2), 209-220, 2016 | 11 | 2016 |
| Are price discounts on sugar-sweetened beverages (SSB) linked to household SSB purchases?–a cross-sectional study in a large US household and retail scanner database Y Zhong, AH Auchincloss, MF Stehr, BA Langellier Nutrition journal 20, 1-12, 2021 | 10 | 2021 |
| Treatment patterns, healthcare resource utilization, and costs in patients with moderate‐to‐severe psoriasis treated with systemic therapy in Japan: A retrospective claims … Y Tada, H Kim, D Spanopoulos, K Habiro, K Tsuritani, Y Yamada, ... The Journal of Dermatology 49 (11), 1106-1117, 2022 | 8 | 2022 |
| Costs of care for patients receiving chemotherapy for advanced bladder cancer AM Kamat, X Cao, J He, Y Zhong, AY Shah, K Flannery J Clin Pathways 3 (10), 63-70, 2017 | 8 | 2017 |
| A discrete choice experiment on oral and injection treatment preferences among moderate‐to‐severe psoriasis patients in Japan M Komine, H Kim, J Yi, Y Zhong, Y Sakai, B Crawford, K Habiro, Y Hikichi, ... The Journal of Dermatology 50 (6), 766-777, 2023 | 6 | 2023 |
| Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies S Thai, J Zhuo, Y Zhong, Q Xia, X Chen, Y Bao, D Dhanda, L Priya, JJ Wu Journal of Dermatological Treatment 34 (1), 2176708, 2023 | 5 | 2023 |
